| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| P2093 | author name string | Cor H J Lamers | |
| Richard A Morgan | |||
| Zhili Zheng | |||
| Marc R Theoret | |||
| Jeremy L Davis | |||
| P2860 | cites work | Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors | Q45753115 |
| Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy | Q45858516 | ||
| T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients | Q45876112 | ||
| Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells | Q48587406 | ||
| Tumor-specific cytolysis by lymphocytes infiltrating human melanomas | Q69738303 | ||
| Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience | Q83222464 | ||
| Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen | Q24623215 | ||
| Cancer regression in patients after transfer of genetically engineered lymphocytes | Q24654976 | ||
| Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes | Q24676216 | ||
| Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 | ||
| T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing | Q33528336 | ||
| T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies | Q33530527 | ||
| Targeting p53 as a general tumor antigen | Q33638172 | ||
| Immune responses to adenovirus and adeno-associated virus in humans. | Q33874473 | ||
| Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells | Q33927506 | ||
| Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction | Q34354588 | ||
| Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. | Q34657661 | ||
| Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability | Q36286127 | ||
| A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer | Q36299662 | ||
| Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells | Q36326582 | ||
| Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes | Q36327157 | ||
| Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions | Q36713758 | ||
| Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition | Q37197942 | ||
| Enhanced T cell receptor gene therapy for cancer | Q37702226 | ||
| The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies | Q40165690 | ||
| Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy | Q44134992 | ||
| Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. | Q44232574 | ||
| Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability. | Q45081770 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| patient | Q181600 | ||
| gene therapy | Q213901 | ||
| P304 | page(s) | 5852-5861 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials | |
| P478 | volume | 16 |
| Q52323967 | A humanized TCR retaining authentic specificity and affinity conferred potent anti-tumor cytotoxicity. |
| Q47549907 | A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy |
| Q39018359 | A novel murine T-cell receptor targeting NY-ESO-1. |
| Q60913472 | A rare population of tumor antigen-specific CD4CD8 double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells |
| Q37257207 | Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology |
| Q27004178 | Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook |
| Q38391528 | Adoptive cellular therapy: a race to the finish line. |
| Q38291751 | Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors |
| Q38170501 | Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation |
| Q37225251 | An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells. |
| Q37919589 | Biomarkers in T cell therapy clinical trials |
| Q36637039 | Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy |
| Q38011650 | Challenges in T cell receptor gene therapy. |
| Q28269352 | Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance |
| Q34511646 | Clinical application of genetically modified T cells in cancer therapy |
| Q88010589 | Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma |
| Q49829282 | Current Status of Gene Engineering Cell Therapeutics |
| Q35135031 | Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer |
| Q39391468 | Development of novel antigen receptors for CAR T-cell therapy directed toward solid malignancies |
| Q37401728 | Domain-swapped T cell receptors improve the safety of TCR gene therapy |
| Q38777742 | Driving gene-engineered T cell immunotherapy of cancer |
| Q41069577 | Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer |
| Q33578792 | Engineered T cells for cancer treatment |
| Q55086081 | Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. |
| Q89576430 | Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy |
| Q39037477 | Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials |
| Q91756196 | Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer |
| Q38123667 | Gene-engineered T cells for cancer therapy |
| Q35960524 | Generation of T-cell receptors targeting a genetically stable and immunodominant cytotoxic T-lymphocyte epitope within hepatitis C virus non-structural protein 3. |
| Q26995677 | Genetic engineering with T cell receptors |
| Q37587362 | Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies. |
| Q38289029 | Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies |
| Q90366900 | High-affinity T cell receptors for adoptive cell transfer |
| Q47222791 | Hitting the Target: How T Cells Detect and Eliminate Tumors |
| Q28727481 | How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer |
| Q38899466 | Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice |
| Q50005900 | Identification of α-fetoprotein-specific T cell receptors for hepatocellular carcinoma immunotherapy |
| Q92379222 | Immune cell therapy for hepatocellular carcinoma |
| Q27693338 | In vivo imaging of therapy-induced anti-cancer immune responses in humans |
| Q41114267 | In-depth Characterization of a TCR-specific Tracer for Sensitive Detection of Tumor-directed Transgenic T Cells by Immuno-PET |
| Q36026142 | Mouse and Human CD1d-Self-Lipid Complexes Are Recognized Differently by Murine Invariant Natural Killer T Cell Receptors |
| Q36480611 | Phenotypes and clinical significance of circulating CD4(+)CD25(+) regulatory T cells (Tregs) in patients with acute-on-chronic liver failure (ACLF). |
| Q92245345 | T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance |
| Q38068003 | T cell-based gene therapy of cancer |
| Q37466219 | T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. |
| Q24632975 | T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia |
| Q38820650 | T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells |
| Q28081611 | T-cell receptor gene therapy--ready to go viral? |
| Q38735008 | T-cell target antigens across major gynecologic cancers |
| Q37012701 | Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA |
| Q37592957 | Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy. |
| Q92091538 | Targeting cancers through TCR-peptide/MHC interactions |
| Q34309388 | The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors |
| Q50999703 | The mutational status of p53 can influence its recognition by human T-cells. |
| Q34592273 | Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity |
| Q45872498 | Unbiased Identification of T-Cell Receptors Targeting Immunodominant Peptide-MHC Complexes for T-Cell Receptor Immunotherapy. |
Search more.